First Dechra’s FDA approval for US generic entrant antibiotic

Dechra, an international specialist veterinary pharmaceuticals company, has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.

The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney’s development pipeline since it acquired the US-based business and clearly demonstrates the capabilities of our specialist pharma team, a key resource to the Group, the company said on Friday.

Commenting on the approval Dechra’s Chief Executive Officer, Ian Page said:

“We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra’s position in the US market.”

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s